Healthcare
0
Some hopeful trends on opioid overdoses (finally) – Healthcare Economist
0

While opioid overdoses have been on the rise for decades, recent trends offer a ray of hope. NPR Reports: For the ...

0
Why is the market design for innovative pharmaceuticals not well understood? – Healthcare Economist
0

That is the title of a fantastic editorial by Olivença and others (2024)Many people, when they look at drug prices, think they are "too high" or "too low." ...

0
Does PBM Market Share Vary by Payer Type? – Healthcare Economist
0

An article by Qato and others (2024) quantifies the degree of concentration in the pharmacy benefit manager (PBM) market. ...

0
What is the right sample size for a qualitative interview study? – Healthcare Economist
0

The answer to this question, of course, depends on your specific research question. However, it is useful to review what ...

0
How should family spillover effects be measured in HTA? – Healthcare Economist
0

An article by Campbell et al. (2024) provides some guidance. The authors developed a set of recommendations based on a ...

0
Health care for workers – Healthcare Economist
0

On this Labor Day, how is health care evolving for workers and businesses? First, health care spending is increasing, with costs rising faster than ...

0
How to use the RE-AIM framework to evaluate public health interventions – Healthcare Economist
0

The RE-AIM framework developed by Glasgow et al. (1999) It has five evaluation components. Reach: the proportion of ...

0
What are the potential productivity impacts of new medications that treat Medicare beneficiaries? – Healthcare Economist
0

A key aspect of many medications is that they not only help people feel better, but often these medications can help them ...

0
Impact of genericization on drug prices and treatment value across 8 countries – Healthcare Economist
0

An interesting study of Miquel Serra-Burriel et al. (2024) It examines the impact of genericisation on drug prices in ...

0
Medicare Drug Price Negotiation leads to 38% to 79% price decrease – Healthcare Economist
0

Medicare drug price negotiation is here. Medicare's maximum fair prices (MFPs) result in discounts of between 38% and 79%. In fact, the actual discounts ...

Tools4BLS
Logo
Register New Account
Compare items
  • Total (0)
Compare
0
Shopping cart